FdaApplication
NDA 213260
Identifiers
- fda_app_no: NDA213260
Properties
| Property | Value |
|---|---|
| applicant_name | CMP DEVELOPMENT LLC |
| application_type | NDA |
| approval_date | 2023-02-01 |
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ATORVALIQ | ATORVASTATIN CALCIUM | 20MG/5ML | SUSPENSION;ORAL |
1 product